HIV
GSK announces results of three year trial into long-lasting HIV injection
October 30, 2018Manufacturing and Production GSK, HIV, drugs, injection, medication
GlaxoSmithKline have announced the results of a three year investigation into a long acting, injectable, two-drug HIV regimen at the …
J&J announce promising Phase 1/2a results for HIV vaccine
October 23, 2018Manufacturing and Production AIDS, HIV, J&J, JJ, Vaccine, infectious diseases
The world may be one step closer to discovering a preventative vaccine for HIV following American multinational Johnson & Johnson’s …
Researchers launch Phase 1 trial of HIV vaccine
October 18, 2018Research and Development AIDS, HIV, Vaccine, infection, resdearch
Researchers working with the non-profit organisation the International AIDS Vaccine Initiative (IAVI) have announced the launch of a Phase I …
NHS England to fund availability of Janssen’s single tablet HIV combo Symtuza
October 1, 2018Sales and Marketing HIV, Janssen, NHS, Symtuza, pharma
Great news for HIV patients in the UK as Janssen reveals that NHS England will provide critical funding for its …
Antibody therapy supresses HIV for months after treatment, study shows
October 1, 2018Sales and Marketing HIV, immunology, immunotherapy, nature, research
Researchers from the New York City based Rockefeller University have developed a novel immunotherapy, which is capable of suppressing HIV …
HIV on the rise among straight men in Australia
September 24, 2018Medical Communications, Sales and Marketing AIDS, Aboriginal, Australia, HIV, Kirby Institute
The number of new HIV diagnoses is on the rise among heterosexual men in Australia, according to a new report …
Ibalisumab effective in in treating multidrug resistant HIV
August 16, 2018Research and Development AIDS, HIV, multidrug resistance, phase 3
The monoclonal antibody Ibalizumab has shown significant antiviral activity against multidrug resistant HIV infections, according to the results of a …
Janssen and ViiV’s monthly injectable HIV combo proves non-inferior to daily standard of care
August 15, 2018Research and Development HIV, Janssen, ViiV Healthcare, pharma
Janssen and GSK’s ViiV Healthcare have unveiled strong new Phase 3 data on its two-drug regimen, injected once a month, …
Those at risk of HIV to be offered PrEP drugs in England and Northern Ireland
July 27, 2018Medical Communications AIDS, England, HIV, PrEP, Terrence Higgins Trust
Those at risk of contracting HIV will now be offered PrEP drugs in England and Northern Ireland through a programme …
Janssen’s Symtuza scores approval with the FDA in HIV-1
July 18, 2018Sales and Marketing HIV, Janssen, Symtuza, pharma
Janssen has announced that Symtuza (D/C/F/TAF) has received approval from the FDA in the treatment of human immunodeficiency virus type …
Abivax drug lowers HIV DNA in blood and tissue, but has the opposite effect for some
July 4, 2018Research and Development Abivax, HIV, pharma
Biotechnology firm Abivax has lifted the curtain on new Phase 2a data for its HIV therapy ABX464, showing that the …
Top Ten most popular articles on Pharmafile.com this week
June 29, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing HIV, J&J, JJ, Remicade, Roche, biosimilar Amgen, lung cancer, multiple sclerosis, pharma
Summer seems to be in full swing as we reach the end of June, so it’s time to look back …
European Commission greenlights Gilead’s Biktarvy for HIV-1
June 25, 2018Sales and Marketing Biktarvy, EU, Europe, European Commission, HIV, HIV-1, pharma
Good news for Gilead and HIV patients across the European Union today as the prominent pharma firm announced that its …
Top Ten most popular articles on Pharmafile.com this week
June 1, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing AI, Allergan, AstraZeneca, Cancer, Gilead, HIV, J&J, JJ, google, machine learning, melanoma, pharma, top ten
The first day of June – time for another top ten run-down. It’s been a week somewhat characterised by trial …
Insider Interview: Gilead’s fight against HIV comes into bloom
May 30, 2018Business Services, Manufacturing and Production, Medical Communications, Research and Development, Sales and Marketing Gilead, HIV, Insider Interview, pharma
Mike Elliott, Vice President of Medical Affairs at Gilead (pictured, right), chats about the company’s sponsorship of a ‘A life …
Latest content
Long-acting therapies set to reshape HIV treatment market
MHRA approves Romvimza for tenosynovial giant cell tumour
